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Abstract
Background
Cancer causes significant morbidity and mortality among HIV patients in the US due to
extended life expectancy with access to effective antiretroviral therapy. Low, detectable HIV
RNA has been studied as a risk factor for adverse health outcomes, but its clinical impact on
cancer risk remains unclear. The objective of this study was to determine whether HIV RNA
<1,000 copies/mL six months after starting therapy was associated with 10-year first cancer
risk.
Methods
We followed 7,515 HIV therapy initiators from a US-based multicenter clinical cohort from
1998 to 2014. We used nonparametric multiple imputation to account for viral loads that fell
below assay detection limits, and categorized viral loads six months after therapy initiation
into four groups: <20, 20–199, 200–999, and >999 copies/mL. We calculated estimates of
the cumulative incidence of cancer diagnosis, accounting for death as a competing event.
Inverse probability of exposure and censoring weights were used to control for confounding
and differential loss to follow up, respectively.
PLOS ONE | https://doi.org/10.1371/journal.pone.0197665 June 5, 2018 1 / 14
a1111111111
a1111111111
a1111111111
a1111111111
a1111111111
OPENACCESS
Citation: Lee JS, Cole SR, Achenbach CJ, Dittmer
DP, Richardson DB, Miller WC, et al. (2018) Cancer
risk in HIV patients with incomplete viral
suppression after initiation of antiretroviral therapy.
PLoS ONE 13(6): e0197665. https://doi.org/
10.1371/journal.pone.0197665
Editor: Cristian Apetrei, University of Pittsburgh
Centre for Vaccine Research, UNITED STATES
Received: March 9, 2018
Accepted: May 7, 2018
Published: June 5, 2018
Copyright: © 2018 Lee et al. This is an open access
article distributed under the terms of the Creative
Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in
any medium, provided the original author and
source are credited.
Data Availability Statement: CNICS data are
available to any investigator upon concept proposal
review and approval by the CNICS Research
Coordinating Committee. Information about CNICS
and its data sharing policy is available here: https://
www.uab.edu/cnics/.
Funding: This work was supported by National
Institutes of Health grants T32 AI007001, R01
AI100654, U01 AI069918, and R01 AG053100.
CNICS is an NIH-funded program (R24 AI067039)
made possible by the National Institute of Allergy
Results
Crude 10-year first cancer risk in the study sample was 7.03% (95% CI: 6.08%, 7.98%), with
the highest risk observed among patients with viral loads between 200 and 999 copies/mL six
months after ART initiation (10.7%). After controlling for baseline confounders, 10-year first
cancer risk was 6.90% (95% CI: 5.69%, 8.12%), and was similar across viral load categories.
Conclusion
Overall risk of first cancer was not associated with incomplete viral suppression; however,
cancer remains a significant threat to HIV patients after treatment initiation. As more HIV
patients gain access to treatment in the current “treat all” era, occurrences of incomplete
viral suppression will be observed more frequently in clinical practice, which supports contin-
ued study of the role of low-level HIV RNA on cancer development.
Introduction
Effective antiretroviral therapy (ART) suppresses human immunodeficiency virus (HIV) levels
to below the detection limits of assays used in clinical practice in the United States. Uptake of
ART has resulted in lower incidence of acquired immune deficiency syndrome (AIDS)-defin-
ing illnesses, prolonged survival, and rising incidence of non-AIDS-defining cancers and
chronic diseases among people living and aging with HIV [1]. Cancer is the second-leading
cause of death among both men and women in the US [2], and is also a significant cause of
morbidity and mortality among HIV patients [1, 3]. The risk of developing specific cancers
may be higher among people infected with HIV compared to the general population due to
immunosuppression, oncogenic viral coinfections, and elevated prevalence of certain risk
behaviors, such as smoking and alcohol abuse [4–6].
Not all HIV patients on treatment achieve and maintain undetectable viral loads, and the
impact of low levels of detectable HIV ribonucleic acid (RNA) under 1,000 copies/mL on
the risk of comorbid disease, such as cancer, remains unclear. Incomplete viral suppression
appears to increase the risk of certain cancers [7–9], but the association between early virologic
control and cancer risk has not been rigorously evaluated. Optimally, HIV patients initiating
ART would achieve undetectable HIV RNA within six months [10], and here we explore
whether failure to achieve this milestone is associated with cancer risk. Because low, detectable
HIV RNA may be associated with ongoing inflammation [11, 12], it is biologically plausible
that incomplete viral suppression may have predictive value in assessing the long-term risk of
developing various cancers, particularly those associated with chronic inflammation and viral
coinfection [13, 14]. Failure to suppress HIV RNA after initiation of ART may also be a marker
of suboptimal adherence that could influence long-term clinical outcomes. The objective of
this study is to examine 10-year first cancer risk among HIV patients with a single low-level
viral load measurement under 1,000 copies/mL collected six months after ART initiation,
while accounting for death as a competing risk.
Methods
Study population
We used data from the Center for AIDS Research (CFAR) Network of Integrated Clinical Sys-
tems (CNICS), a multicenter clinical cohort of over 30,000 HIV patients in the United States.
Incomplete HIV RNA suppression and cancer risk
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CNICS maintains a clinical data repository from electronic medical record systems to support
HIV research [15]. The CNICS cohort includes patients aged 18 years and older who initiated
primary care in or after January 1995 at one of eight CFAR sites: Case Western Reserve Uni-
versity; Fenway Community Health Center of Harvard University; Johns Hopkins University;
University of Alabama at Birmingham; University of California, San Diego; University of Cali-
fornia, San Francisco; University of North Carolina at Chapel Hill; and University of Washing-
ton. CNICS is a dynamic cohort, with approximately 1,400 new patients enrolling and 10% of
patients leaving care annually [15].
Upon entry into CNICS, demographic and historical information, including prior diagno-
ses and antiretroviral treatment, was collected. After enrollment, patient data were prospec-
tively captured at clinic visits and include prescribed medications, laboratory test results, and
conditions diagnosed by providers. CNICS participants were typically seen in clinical care
every three to four months, though frequency of follow-up was patient specific. The research
of CNICS was approved by the Office of the Institutional Review Board for Human Use at
the University of Alabama at Birmingham. All participating study sites received consent from
their local institutional review boards to conduct the research activities of CNICS. The study
conducted here, a secondary analysis of extant, de-identified CNICS data, was reviewed by the
Office of Human Research Ethics at the University of North Carolina at Chapel Hill, which
determined that it did not constitute human subjects research.
A total of 27,865 patients entered the CNICS cohort between 1 January 1998 and 31 Decem-
ber 2013. We excluded patients who initiated monotherapy or dual therapy prior to or with
no history of starting combination ART (defined as three or more ART drugs prescribed con-
currently) (n = 3,499), initiated ART prior to entering CNICS (n = 6,405), initiated ART after
31 December 2013 (n = 282), or had no history of initiating ART (n = 4,067). We excluded
patients who were diagnosed with cancer prior to ART initiation (n = 570), were diagnosed
with cancer within six months of starting ART (n = 151), died within six months of starting
ART (n = 99), or did not have at least one viral load measurement six months (-30/+90 days)
after ART initiation (n = 3,285). Patients with missing covariate data (missing race/ethnicity
information [n = 88], no recorded CD4 count six months [-30/+90 days] after ART initiation
[n = 308], no pre-ART viral load measurement collected between 60 days prior to CNICS
entry and ART initiation [n = 261]) or pre-ART viral load measurements that suggested unre-
corded prior exposure to treatment (<1,000 copies/mL) (n = 1,335) were also excluded. The
final study sample comprised 7,515 patients.
Viral load assessment
The exposure of interest was HIV RNA six months (-30/+90 days) after ART initiation. For
patients who had more than one eligible viral load measurement during the specified 120-day
window, we used the measurement that was closest to six months after date of ART initiation.
Viral load measurements were determined by quantitative amplification assays and expressed
as the number of HIV copies per milliliter of blood plasma (copies/mL). Viral load assay sensi-
tivity varied over time and by CNICS site; the lower limits of detection for the most commonly
used assays were 20, 30, 40, 48, 50, 75, and 400 copies/mL. Observed viral load measurements
six months after ART initiation ranged from 6 to over 4 million copies/mL.
Endpoint ascertainment
The outcome of interest was time from six months after ART initiation to diagnosis of first
invasive cancer, excluding nonmelanoma skin cancer. All cancer cases diagnosed through 31
December 2014 and recorded at CNICS sites were verified by medical record review [16].
Incomplete HIV RNA suppression and cancer risk
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Cancer data collected by CNICS included date of diagnosis, tumor site, diagnosis method (his-
topathology, clinical exam, radiography, or historical information), histology, stage, and grade.
Death from any cause was considered a competing risk in the analysis. National Death
Index and state death certificate records were queried regularly by all CNICS sites to confirm
recorded dates of deaths.
Statistical analysis
The start of follow-up for each patient was six months after date of ART initiation. Patients
were followed until the earliest of the following: first cancer diagnosis, death, or loss to follow-
up (defined as no recorded clinic visit, laboratory result, or hospitalization for 18 months).
Death from any cause without a cancer diagnosis was considered a competing event. Data
were administratively censored after 10 years or on 31 December 2014.
We used a proportional subdistribution hazards model [17] to compute nonparametric esti-
mates of the cumulative incidence function of being diagnosed with incident cancer in the pres-
ence of the competing risk of death. We calculated 10-year risk differences and risk ratios and
constructed risk curves stratified by viral load category [18]. We drew 200 nonparametric boot-
strap samples with replacement from the original study population to estimate standard errors.
The majority of viral load observations included in our analyses were reported to be below
specified lower limits of detection (i.e., 20, 30, 40, 48, 50, 75, and 400 copies/mL). For the
original study population and each bootstrap sample, we used a nonparametric imputation
approach with a censoring score model to account for left-censored viral load data [19]. For
each viral load observation, we used logistic regression to estimate the conditional probability
of left censoring given age, sex, race/ethnicity, sexual identity, injection drug use, CD4 count,
clinical AIDS status, year of ART initiation, ART regimen, pre-ART viral load, chronic hepati-
tis status, statin use, smoking status, at-risk alcohol use, CNICS site, death, and incident cancer
[20]. Restricted quadratic splines were used to model age and CD4 count, with knots at the 5th,
35th, 65th, and 95th percentiles [21]. We computed nonparametric maximum likelihood esti-
mates [22, 23] of the distribution function of viral load, stratified by quintiles of the predicted
probability of being left censored. These estimates were used to impute left-censored viral load
observations, and imputed viral load values were bounded between zero and the detection
limit of the viral load assay used. Thirty imputed datasets were generated for the original study
population and each bootstrap sample.
Patients were assigned to the following exposure categories based on their observed or
imputed viral load at baseline (six months after ART initiation): <20, 20 to 199, 200 to 999,
and>999 copies/mL. Because the US Department of Health and Human Services and the
AIDS Clinical Trials Group currently define virologic failure as one confirmed viral load mea-
surement at or above 200 copies/mL [10], we divided low-level viral loads under 1,000 copies/
mL into two categories, 20 to 199 copies/mL, and 200 to 999 copies/mL. The reference cate-
gory was viral load<20 copies/mL.
We used inverse probability of exposure weights [24, 25] to control for differences at base-
line among patients across the four viral load categories and calculate cumulative incidence
estimates standardized to the total study population. Sex, race/ethnicity, sexual identity, and
injection drug use were assessed at entry into the CNICS cohort. Pre-ART viral load, ART
regimen, and year of ART initiation were assessed at ART initiation. Age, CD4 count, clinical
AIDS status, chronic hepatitis status, statin use, smoking status, at-risk alcohol use, and
CNICS site were assessed at study baseline. Restricted quadratic splines were used to model
age and CD4 count. Using a multinomial logistic regression model, we estimated the condi-
tional probability of having a viral load in each viral load category.
Incomplete HIV RNA suppression and cancer risk
PLOS ONE | https://doi.org/10.1371/journal.pone.0197665 June 5, 2018 4 / 14
Additionally, we estimated inverse probability of censoring weights to account for poten-
tially informative loss to follow-up by viral load category. The inverse probability of exposure
and inverse probability of censoring weights were stabilized, and the product of the stabilized
weights had a mean of 1.0 in the imputed datasets of the original study sample, with a mini-
mum of 0.12 and maximum of 13. We used SAS version 9.4 (SAS Institute Inc., Cary, NC) for
analyses, and R version 3.3.1 (R Foundation for Statistical Computing, Vienna, Austria) for
figures.
Results
We identified 7,515 CNICS patients who met our study inclusion criteria (Table 1). Median
age at baseline (six months after ART initiation) was 39 (interquartile range [IQR]: 32, 46)
years, 82% were male, 44% were white, 37% were black/African American, 61% identified as
Table 1. Demographic, clinical, and behavioral characteristics of 7,515 CNICS patients six months after ART initiation, averaged over 30 imputations, between 1
July 1998 and 30 June 2014.
Characteristic Total
n = 7,515
<20 cpm
n = 4,281
20–199 cpm
n = 1,694
200–999 cpm
n = 393
>999 cpm
n = 1,147
No. (%) No. (%) No. (%) No. (%) No. (%)
Age, years a 39 (32, 46) 39 (32, 47) 40 (33, 46) 40 (34, 47) 39 (32, 45)
Male b 6,180 (82.2) 3,553 (83.0) 1,421 (82.5) 324 (80.7) 882 (76.9)
Race/ethnicity b
White, non-Hispanic 3,343 (44.5) 2,008 (46.9) 759 (44.8) 160 (40.7) 416 (36.3)
Black, non-Hispanic 2,800 (37.3) 1,426 (33.3) 627 (37.0) 181 (46.0) 566 (49.3)
Other, non-Hispanic 375 (5.0) 238 (5.6) 78 (4.6) 16 (4.2) 43 (3.7)
Hispanic 997 (13.3) 609 (14.2) 230 (13.6) 36 (9.1) 122 (10.6)
MSM, ever b 4,611 (61.4) 2,753 (64.3) 1,037 (61.2) 224 (56.9) 597 (52.0)
IDU, ever b 938 (12.5) 451 (10.5) 205 (12.1) 67 (17.1) 215 (18.7)
Smoking, ever 2,474 (32.9) 1,366 (31.9) 555 (32.8) 129 (32.8) 424 (37.0)
At-risk alcohol use, ever 1,125 (15.0) 609 (14.2) 244 (14.4) 58 (14.6) 214 (18.7)
Pre-ART viral load, cpm a,c 73,320 (22,000; 234,048) 55,133 (17,296; 166,966) 109,225 (35,253; 349,189) 103,356 (35,573; 427,215) 93,071 (30,122; 299,230)
Year of ART initiation a,c 2007 (2003, 2010) 2008 (2004, 2010) 2006 (2002, 2009) 2006 (2002, 2009) 2005 (2001, 2008)
ART regimen c
NNRTI-based 3,570 (47.5) 2,335 (54.5) 691 (40.8) 136 (34.6) 409 (35.7)
PI-based 2,997 (39.9) 1,420 (33.2) 782 (46.2) 209 (53.2) 586 (51.1)
INSTI-based 405 (5.4) 290 (6.8) 75 (4.4) 10 (2.5) 30 (2.6)
Other 543 (7.2) 236 (5.5) 147 (8.7) 38 (9.6) 122 (10.6)
CD4 count, cells/mm3 a 356 (201, 537) 412 (254, 581) 338 (197, 511) 299 (177, 456) 204 (75, 362)
Clinical AIDS diagnosis 1,985 (26.4) 918 (21.4) 521 (30.7) 130 (33.1) 417 (36.4)
Chronic hepatitis B 193 (2.6) 82 (1.9) 50 (3.0) 11 (2.9) 49 (4.3)
Chronic hepatitis C 612 (8.1) 307 (7.2) 135 (8.0) 34 (8.8) 135 (11.8)
Statin use, ever 236 (3.1) 158 (3.7) 45 (2.6) 11 (2.8) 22 (1.9)
Abbreviations: AIDS, acquired immunodeficiency syndrome; ART, antiretroviral therapy; CNICS, Center for AIDS Research Network of Integrated Clinical Systems;
cpm, copies per milliliter; INSTI, integrase strand transfer inhibitor; IDU, injection drug use; IQR, interquartile range; MSM, men who have sex with men; NNRTI,
non-nucleoside reverse transcriptase inhibitor; PI, protease inhibitor.
a Median (interquartile range).
b Assessed at entry into CNICS cohort.
c Assessed at ART initiation.
https://doi.org/10.1371/journal.pone.0197665.t001
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men who have sex with men, and 12% reported having ever injected drugs. Median pre-ART
viral load was 73,320 (IQR: 22,000, 234,048) copies/mL, median year of ART initiation was
2007 (IQR: 2003, 2010), and median CD4 count was 356 (IQR: 201, 537) cells/mm3. At base-
line, 26% of study patients had been diagnosed with AIDS, 40% had been prescribed a protease
inhibitor (PI)-based regimen, and 48% were prescribed a non-nucleoside reverse transcriptase
inhibitor (NNRTI)-based regimen. Patients were followed for a median of 4.9 (IQR: 2.7, 8.1)
years, for a total of 40,110 person-years. We recorded 290 cancer diagnoses during the study
period, and 1,731 (23%) patients were lost to follow up.
Of the 7,515 patients included in the study, 68% had viral loads six months after ART initia-
tion that were below assay detection limits. After imputation, 56% of viral loads were under 20
copies/mL, 23% were between 20 and 199 copies/mL, 5% were between 200 and 999 copies/
mL, and 15% were over 999 copies/mL. Plots of the distribution of viral load comparing our
nonparametric multiple imputation approach to ad hoc substitution (replacing left-censored
viral load observations with half of the detection limit of the viral load assay) are shown in
S1 Fig.
Patients differed across viral load categories at baseline (Table 1). Patients with suppressed
viral loads <20 copies/mL six months after ART initiation were more likely to be white, iden-
tify as men who have sex with men, have higher CD4 counts, have lower pre-ART viral loads,
have started ART in the latter half of the study period, have been prescribed an NNRTI-based
regimen, and have been prescribed statins. Patients with viral loads <20 copies/mL six months
after starting ART were less likely to report injection drug use, have been prescribed a PI-
based regimen, have chronic hepatitis, report having ever smoked, or report at-risk alcohol
use.
The most common cancers observed in our study population were non-Hodgkin lym-
phoma (n = 39 cases, or 13.4% of all cancer cases), Kaposi sarcoma (n = 37; 12.8%), lung cancer
(n = 30, 10.3%), Hodgkin lymphoma (n = 26; 9.0%), prostate cancer (n = 22; 7.6%), anal cancer
(n = 18; 6.8%), breast cancer (n = 14; 4.8%), and liver cancer (n = 14; 4.8%) (Table 2). Crude
cancer risk in the study sample was 7.03% (95% confidence interval [CI]: 6.08%, 7.98%)
(Table 3). The highest crude cancer risk was observed among patients with viral loads between
200 and 999 copies/mL six months after ART initiation (10.7%), with risk of cancer diagnosis
ranging from 6.60% to 7.67% in the other three viral load categories.
After controlling for baseline characteristics, overall 10-year cancer risk was 6.90% (95%
CI: 5.69%, 8.12%), with little variation in cancer risk by viral load category (range: 6.76% to
7.44%). The cumulative cancer incidence estimate for patients with viral loads between 200
and 999 copies/mL was markedly reduced after adjustment (crude risk of 10.7% vs. standard-
ized risk of 6.82%); race/ethnicity, year of ART initiation, ART regimen, baseline CD4 count,
and study site accounted for 75% of the change in estimate in this viral load category. Among
patients with viral loads between 200 and 999 copies/mL six months after ART initiation who
were diagnosed with cancer, 62% were black (compared to 47% of all cases in the total study
population), 53% started ART between 1998 and 2000 (vs. 21%), 63% had been prescribed a
PI-based regimen (vs. 46%), and 48% had a CD4 count of less than 200 cells/mm3 six months
after starting therapy (vs. 36%). Crude and standardized risk curves for 10-year cumulative
cancer incidence are shown in Fig 1.
The overall standardized risk of death without a cancer diagnosis, which was considered a
competing risk in the analysis, was 12.2% (95% CI: 10.2%, 14.2%) (Table 4, Fig 2). The risk
of death differed by viral load category, ranging from 10.7% among patients with viral loads
under 20 copies/mL to 18.1% among patients with viral loads of at least 1,000 copies/mL six
months after starting ART.
Incomplete HIV RNA suppression and cancer risk
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Discussion
Our objective was to evaluate 10-year cancer risk among HIV patients on antiretroviral ther-
apy with low viral load under 1,000 copies/mL, while accounting for death from any cause as
a competing event. Crude 10-year risk of first cancer diagnosis was highest for patients with
viral loads between 200 and 999 copies/mL after six months of therapy, though this was largely
due to imbalances in race, year of ART initiation, ART regimen, CD4 count, and study site;
after controlling for these factors and other baseline confounders, there was no association
between HIV RNA six months after ART initiation and first cancer risk.
Nearly 70% of all viral load observations used in the analysis fell below assay detection lim-
its, which was expected given that the study population had been on ART for six months at
Table 2. Number (%) of cancers observed in 7,515 CNICS patients, averaged over 30 imputations (rounded to nearest integer).
Total
n = 7,515
<20 cpm
n = 4,281
20–199 cpm
n = 1,694
200–999 cpm
n = 393
>999 cpm
n = 1,147
All cancers 290 (100) 152 (100) 62 (100) 22 (100) 54 (100)
Non-Hodgkin lymphoma 39 (13.4) 17 (11.2) 11 (17.7) 2 (9.1) 9 (16.7)
Kaposi sarcoma 37 (12.8) 17 (11.2) 5 (8.1) 3 (13.6) 12 (22.2)
Lung cancer 30 (10.3) 18 (11.8) 6 (9.7) 1 (4.5) 5 (9.3)
Hodgkin lymphoma 26 (9.0) 18 (11.8) 5 (8.1) 1 (4.5) 2 (3.7)
Prostate cancer 22 (7.6) 12 (7.9) 8 (12.9) 1 (4.5) 1 (1.9)
Anal cancer 18 (6.8) 8 (5.3) 5 (8.1) 3 (13.6) 4 (7.4)
Breast cancer 14 (4.8) 10 (6.6) 3 (4.8) 0 1 (1.9)
Liver cancer 14 (4.8) 7 (4.6) 2 (3.2) 1 (4.5) 4 (7.4)
Skin cancer (melanoma) 11 (3.8) 4 (2.6) 3 (4.8) 1 (4.5) 3 (5.6)
Oral cavity and pharyngeal cancer 10 (3.4) 5 (3.3) 1 (1.6) 1 (4.5) 3 (5.6)
Kidney cancer 8 (2.8) 4 (2.6) 1 (1.6) 2 (9.1) 1 (1.9)
Colon cancer 6 (2.3) 4 (2.6) 2 (3.2) 0 0
Leukemia 6 (2.3) 3 (2.0) 1 (1.6) 0 2 (3.7)
Laryngeal cancer 5 (1.7) 3 (2.0) 2 (3.2) 0 0
Multiple myeloma 5 (1.7) 2 (1.3) 2 (3.2) 0 2 (3.7)
Cervical cancer 4 (1.4) 2 (1.3) 1 (1.6) 0 1 (1.9)
Esophageal cancer 3 (1.0) 2 (1.3) 1 (1.6) 0 0
Uterine cancer 3 (1.0) 2 (1.3) 1 (1.6) 0 0
Thyroid cancer 3 (1.0) 2 (1.3) 0 1 (4.5) 0
Brain and nervous system cancer 2 (0.7) 2 (1.3) 0 0 0
Testicular cancer 2 (0.7) 2 (1.3) 0 0 0
Rectal and rectosigmoid cancer 2 (0.7) 1 (0.7) 1 (1.6) 0 0
Peritoneal & retroperitoneal cancer 2 (0.7) 1 (0.7) 0 0 1 (1.9)
Bladder cancer 1 (0.3) 1 (0.7) 0 0 0
Ovarian cancer 1 (0.3) 1 (0.7) 0 0 0
Soft tissue cancer 1 (0.3) 1 (0.7) 0 0 0
Stomach cancer 1 (0.3) 1 (0.7) 0 0 0
Vaginal cancer 1 (0.3) 0 1 (1.6) 0 0
Vulvar cancer 1 (0.3) 0 0 1 (4.5) 0
Pancreatic cancer 1 (0.3) 0 0 0 1 (1.9)
Small intestine cancer 1 (0.3) 0 0 0 1 (1.9)
Other (unspecified site) 8 (2.8) 3 (2.0) 1 (1.6) 3 (13.6) 1 (1.9)
Abbreviation: CNICS, Center for AIDS Research Network of Integrated Clinical Systems; cpm, copies per milliliter.
https://doi.org/10.1371/journal.pone.0197665.t002
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baseline. Prior studies have typically replaced viral load observations below assay detection
limits with a constant value, which can result in substantial bias, particularly when the propor-
tion of censoring is high [26, 27]. In our previous study of total mortality in a similar sample of
CNICS patients, using a simple substitution approach to account for left-censored viral loads
resulted in violations of positivity, unstable weights, and upwardly biased hazard ratio esti-
mates [19]. Here, we used nonparametric multiple imputation to account for left-censored
viral loads. This approach allowed for the comparison of undetectable viral load observations
collected over time using assays with different detection limits, without imposing assumptions
about the underlying distribution of viral load, and likely resulted in less biased cumulative
incidence estimates.
Studies that characterize cancer risk often measure incidence rates, typically expressed as
the number of cancer events per 100,000 person-years, which assume that incident cancers
occur at a constant rate over time. Here we estimated the probability of developing cancer over
a specific 10-year period, which may provide a more intuitive measure of cumulative cancer
risk. Additionally, a number of previous studies evaluating cancer trends among people with
HIV have censored deaths in their analyses rather than using a competing risks approach.
Treating deaths as censored observations (i.e., using the Kaplan-Meier survival function or
standard Cox proportional hazards estimates) ignores the fact that HIV patients may die
before being diagnosed with cancer, and will thereby overestimate cancer risk. While censor-
ing competing events may not lead to significant bias when the risk of the competing event is
rare, we observed nearly twice as many deaths as first cancer diagnoses (560 deaths vs. 290 can-
cer diagnoses) in our study sample of HIV patients on treatment. Moreover, censoring com-
peting events may lead to additional bias when the risk of the competing event is differential
by exposure, as was the case in this study. We expect that we arrived at less biased risk esti-
mates by modeling the cumulative incidence function of cancer, while explicitly accounting
for death from any cause without a cancer diagnosis as a competing risk.
We did not account for adherence, switching, or cessation of ART regimen in the analyses.
For each treatment-naïve patient, we considered the first recorded date of concurrent prescrip-
tion of three or more ART drugs as an indicator of starting a combination ART regimen, and
Table 3. Crude and standardized 10-year cumulative incidence, risk difference, and risk ratio estimates for first cancer diagnosis in 7,515 CNICS patients, averaged
over 30 imputations.
No. of events No. of patients Person- years Crude Standardized a
Risk, %
(95% CI)
RD, %
(95% CI)
RR
(95% CI)
Risk, %
(95% CI)
RD, %
(95% CI)
RR
(95% CI)
Total 290 7,515 40,110 7.03 (6.08,
7.98)
6.90 (5.69,
8.12)
<20 cpm 152 4,281 22,392 6.60 (5.34,
7.86)
0 1 6.76 (5.12,
8.39)
0 1
20 to 199 cpm 62 1,694 9,625 6.71 (5.25,
8.17)
0.10 (-1.74,
1.94)
1.02 (0.73,
1.30)
6.88 (5.08,
8.68)
0.12 (-2.08,
2.33)
1.02 (0.68,
1.36)
200 to 999
cpm
22 393 2,124 10.7 (5.74,
15.6)
4.08 (-0.92,
9.08)
1.62 (0.83,
2.40)
6.82 (3.50,
10.1)
0.06 (-3.73,
3.86)
1.01 (0.43,
1.59)
>999 cpm 54 1,147 5,969 7.67 (5.31,
10.0)
1.07 (-1.69,
3.84)
1.16 (0.72,
1.61)
7.44 (4.10,
10.8)
0.68 (-3.05,
4.41)
1.10 (0.53,
1.67)
Abbreviations: CI, confidence interval; CNICS, Center for AIDS Research Network of Integrated Clinical Systems; cpm, copies per milliliter; RD, risk difference; RR,
risk ratio.
a Standardized estimates controlled for age, sex, race/ethnicity, male-to-male sexual contact, injection drug use, smoking, at-risk alcohol use, pre-ART viral load, year of
ART initiation, ART regimen, CD4 count, clinical AIDS status, chronic hepatitis status), statin use, and study site.
https://doi.org/10.1371/journal.pone.0197665.t003
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ignored changes in treatment. We assumed that variables included in the analyses were mea-
sured without error, which is unlikely for self-reported behaviors such as tobacco, alcohol, and
illicit drug use; however, we do not expect measurement error of confounders to be differential
by exposure or outcome. Outcome misclassification was minimized in this study as cancer
Fig 1. Crude and standardized risk curves for first cancer diagnosis in 7,515 CNICS patients, stratified by viral load
category, averaged over 100 imputations. Standardized estimates controlled for age, sex, race/ethnicity, male-to-male
sexual contact, injection drug use, smoking, at-risk alcohol use, pre-ART viral load, year of ART initiation, ART
regimen, CD4 count, clinical AIDS status, chronic hepatitis status, statin use, and study site. Solid line represents viral
loads<20 copies/mL, dot-dashed line represents viral loads between 20 and 199 copies/mL, dashed line represents viral
loads between 200 and 999 copies/mL, dotted line represents viral loads>999 copies/mL. (a) Crude; (b) Standardized.
https://doi.org/10.1371/journal.pone.0197665.g001
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cases were confirmed through medical record review, and deaths verified using national and
state death records.
Nearly a quarter of our study sample was lost to follow-up over the study period, and
patients were followed for a median of five years. Given that the outcome of interest was
10-year cancer risk, it would be worthwhile to reassess our risk estimates after additional
person-time has accumulated in the CNICS cohort. Due to the relatively small number of can-
cer cases observed in our study population, our estimates had limited precision and we were
unable to make inferences about the potential relationship between incomplete viral suppres-
sion and specific cancer types. Therefore, pooling data from other clinical cohorts to verify
and expand upon our results is warranted. Nevertheless, we expect that the results of this study
are generalizable to HIV patients receiving care and treatment at academic medical centers
in the US, and we observed clinically meaningful trends that highlight potential avenues for
increased and/or early cancer screening and prevention among people living and aging with
HIV. In this study, non-Hodgkin lymphoma, Kaposi sarcoma, lung cancer, Hodgkin lym-
phoma, prostate cancer, anal cancer, breast cancer, and liver cancer were the most commonly
observed cancer types, consistent with prior studies of cancer in HIV patients after the intro-
duction of ART [1, 3, 28]. This has implications for targeted cancer screening for HIV patients,
including those on successful ART, as well as preventive interventions such as smoking cessa-
tion programs and human papillomavirus and hepatitis B vaccination. We also observed a
higher proportion of Hodgkin lymphoma cases among patients with lower viral loads, possibly
related to immune reconstitution [29].
We observed a 10-year standardized first cancer risk of 6.9% in our sample of HIV patients
after starting therapy, which provides support for existing evidence that cancer poses a signifi-
cant threat to HIV patients after ART initiation, even among patients who have rapidly
achieved viral suppression. Exposure status was based on a single HIV RNA measurement col-
lected approximately six months after ART initiation, as we considered viral suppression at
this time point a relevant marker of early treatment success. However, a single detectable viral
load measurement could represent either a transient increase in viral load or sustained low-
level viremia. While we did not observe an association between early virologic response and
Table 4. Crude and standardized 10-year cumulative incidence, risk difference, and risk ratio estimates for death without a cancer diagnosis in 7,515 CNICS
patients, averaged over 30 imputations.
No. of events No. of patients Person- years rude Standardized a
Risk, %
(95% CI)
RD, %
(95% CI)
RR
(95% CI)
Risk, %
(95% CI)
RD, %
(95% CI)
RR
(95% CI)
Total 560 7,515 40,110 12.7 (11.5,
13.9)
12.2 (10.2,
14.2)
<20 cpm 196 4,281 22,392 8.99 (7.60,
10.4)
0 1 10.7 (8.18,
13.2)
0 1
20 to 199 cpm 112 1,694 9,625 11.5 (9.55,
13.5)
2.55 (0.34,
4.75)
1.28 (1.01,
1.55)
11.5 (9.11,
13.8)
0.74 (-1.68,
3.17)
1.07 (0.83,
1.30)
200 to 999
cpm
37 393 2,124 14.7 (9.55,
19.9)
5.73 (0.29,
11.2)
1.64 (0.99,
2.28)
15.0 (8.86,
21.1)
4.25 (-2.53,
11.0)
1.40 (0.73,
2.06)
>999 cpm 215 1,147 5,969 26.3 (22.9,
29.7)
17.3 (13.6,
21.0)
2.93 (2.31,
3.55)
18.1 (13.7,
22.5)
7.38 (2.40, 12.4) 1.69 (1.14,
2.24)
Abbreviations: CI, confidence interval; CNICS, Center for AIDS Research Network of Integrated Clinical Systems; cpm, copies per milliliter; RD, risk difference; RR,
risk ratio.
a Standardized estimates controlled for age, sex, race/ethnicity, male-to-male sexual contact, injection drug use, smoking, at-risk alcohol use, pre-ART viral load, year of
ART initiation, ART regimen, CD4 count, clinical AIDS status, chronic hepatitis status, statin use, and study site.
https://doi.org/10.1371/journal.pone.0197665.t004
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Fig 2. Crude and standardized risk curves for death without a cancer diagnosis in 7,515 CNICS patients, stratified
by viral load category, averaged over 100 imputations. Standardized estimates controlled for age, sex, race/ethnicity,
male-to-male sexual contact, injection drug use, smoking, at-risk alcohol use, pre-ART viral load, year of ART
initiation, ART regimen, CD4 count, clinical AIDS status, chronic hepatitis status, statin use, and study site. Solid line
represents viral loads<20 copies/mL, dot-dashed line represents viral loads between 20 and 199 copies/mL, dashed
line represents viral loads between 200 and 999 copies/mL, dotted line represents viral loads>999 copies/mL. (a)
Crude; (b) Standardized.
https://doi.org/10.1371/journal.pone.0197665.g002
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subsequent cancer risk in this study, using longitudinal viral load measurements to assess
exposure is warranted to better understand the dynamic nature of HIV RNA suppression.
Continued research on the role of low-level circulating HIV RNA on cancer development is of
particular importance, as occurrences of incomplete viral suppression will be observed more
frequently in clinical practice with more people with HIV gaining access to effective ART in
the current era of universal treatment.
Supporting information
S1 Fig. Distribution of viral loads up to 200 copies/mL for 7,515 CNICS patients, six
months after ART initiation. Dotted line indicates 20 copies/mL. (a) After nonparametric
multiple imputation of left-censored viral load observations, averaged over 30 imputations
of original dataset; (b) After substitution of left-censored viral load observations with half of
detection limit of viral load assay.
(TIF)
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